Biotinoyl Tripeptide-1 299157-54-3

98% up by HPLC, Cosmetic Grade

Product categories

New Products

Product Details

Product Information

Product name	Biotinoyl Tripeptide-1
CAS No.	299157-54-3
Molecular Formula	C24H38N8O6S
Molecular Weight	566.67
Quality Standard	98% up by HPLC, Cosmetic grade
Appearance	White powder

COA of Biotinoyl Tripeptide-1

Items	Specifications	Results
Appearance:	White powder	Conform
Identification	Positive	Conform
Odor&taste	Characteristic	Conform
Mesh size/sieve analysis	Through 80 mesh	Conform
Loss on drying	≤ 8%	3.23%
Heavy metals
Total heavy metals	≤ 10 ppm	Conform
Arsenic	≤ 1 ppm	Conform
Lead	≤ 2 ppm	Conform
Cadmium	≤ 1 ppm	Conform
Hygraryrum	≤ 0.1 ppm	Conform
Residual solvent	Meet Eur. Ph6.0	Conform
Pesticide residue	Meet the requirements	Not detected
Microbiological tests
Total plate count	≤ 5000 cfu/g	Conform
Total Yeast & Mold	≤ 100 cfu/g	< 100 cfu/g
E. Coli	Negative	Negative
Salmonella	Negative	Negative
Staphylococcus	Negative	Negative
Assay(by HPLC)	≥ 98%	98.9%
Conclusion	Meet the specification of requirements

Usage

Biotin tripeptide-1 is an extracellular matrix (ECM) cell-communicating peptide (Palmitoyl Tripeptide-1) that has been conjugated to biotin. It has been found helpful for reducing hair loss, increasing hair growth and making eye lashes appear longer, fuller and stronger. Biotinoyl tripeptide-1 increases the population of anagen hair, which is the active growth phase of hair follicles. It provokes the cells in the roots to divide more rapidly, having an impressive impact on eyelash growth in particular. Biotin tripeptide-1 stimulates the production of adhesion molecules collagen IV and laminin 5 in dermal and epidermal cells (which helps with hair anchorage).

The manufacturer did some in-vitro studies that show the molecule can localize to human hair follicles, inducing keratinocyte proliferation, increasing hair growth by 58% and 121% compared with control follicles when used at concentrations of 2 and 5 pp

Hot Tags : Biotinoyl Tripeptide-1 Biotinoyl Tripeptide Tripeptide Procapil Biotinyl-GHK tripeptide Biotinyl-GHK

Send A Message

Related Products

LIRAGLUTIDE 204656-20-2

Product Information Product name Liraglutide Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]- -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS No. 204656-20-2 Molecular Formula C172H265N43O51 Molecular Weight 3751.20 Storage 2~8℃ Appearance White to off-white crystalline powder COA of Liraglutide Test Specification Results Appearance: White to off-white crystalline powder or lumps White powder Identity: 3751.2±1.0 3751.1 Purity (By HPLC) : Not Less than 98.0%; 99.51% Residual solvents: ≤0.25%total; ≤0.1%individual; ≤0.01%CH2CN Complies Related Peptide Total Impurity ≤ 2.0% Largest Single Impurity ≤ 1.0% TI =0.41% LSI =0.25% Peptide Content: Not Less than 85.0% 87.7% Water (K.F.): Not more than 5% 4.2% Acetate acid: Not more than 10% 8.1% Bacterial Endotoxins Not more than 50IU/mg Complies Usage Function and Usage of Liraglutide 204656-20-2 1、 Type 2 diabetes Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes: · Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia. · Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies). · Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride. · Liraglutide lowers blood triglyceride levels. 2、Obesity Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.